Clinical study data of cabozantinib

Cabozantinib (Cabozantinib), as a multi-target tyrosine kinase inhibitor, has shown broad application prospects in clinical trials. The following is an analysis of cabozantinib’s clinical research data combined with clinical trial data:

1. Renal cell carcinoma (RCC):

Cabozantinib has been studied extensively with positive results in clinical trials for renal cell carcinoma. A Phase III clinical trial (METEOR trial) showed that cabozantinib significantly prolonged progression-free survival (PFS) and overall survival (OS) compared with placebo. The results of the study showed that the PFS in the cabozantinib treatment group was 7.4 months, while the PFS was 3.8 months, and the overall survival was 21.4 months and 16.5 months respectively.

In addition, some phase II clinical trials have also confirmed the efficacy and safety of cabozantinib in the treatment of RCC, further supporting its status as first-line or second-line treatment.

2.Thyroid cancer (TC):

For patients with advanced thyroid cancer, the clinical research data of cabozantinib also shows a certain efficacy. A phase II clinical trial showed that approximately 33% of patients in the cabozantinib treatment group achieved a clinical response of partial response or complete response, and the overall survival was prolonged by approximately 11 months.

In addition, otherIIPhase 1 clinical trials also confirmed the effectiveness of cabozantinib in the treatment of metastatic thyroid cancer and showed good tolerability and safety.

3.Hepatocellular carcinoma (HCC):

In clinical trials for hepatocellular carcinoma, cabozantinib has also shown certain therapeutic potential. A phase III clinical trial (the CELESTIAL trial) confirmed that patients in the cabozantinib treatment group had a significantly longer overall survival and a significant survival advantage over the placebo group. The study results showed that the median overall survival in the cabozantinib treatment group was 10.2 months, while the placebo group was 8.0 months.

In addition, some phase II clinical trials have also confirmed the effectiveness of cabozantinib in the treatment of hepatocellular carcinoma, and have shown certain survival advantages and response rates.

In general, cabozantinib, as a targeted therapy, has demonstrated significant efficacy and safety in clinical trials. It has achieved positive results in the treatment of multiple cancer types, including renal cell carcinoma, thyroid cancer, and hepatocellular carcinoma, providing an effective treatment option for patients with advanced cancer. However, it should be noted that the therapeutic efficacy and safety of cabozantinib still require further research and verification to determine its exact status and optimal application strategy in clinical practice.